Aetna considers donor lymphocyte infusion (DLI) medically necessary for persons who have a prior, medically necessary allogeneic bone marrow or peripheral stem cell transplantation.
Aetna considers the modification of donor lymphocytes (e.g., donor lymphocyte depletion, ex-vivo expansion, expanding antigen-specific T-cell lines, T-cell depletion, genetic modification) experimental and investigational because the clinical value of these approaches in the treatment of malignancies has not been established.
High-dose chemotherapy (HDC) in combination with allogeneic bone marrow transplantation results in remission in significant numbers of patients with chronic myelogenous leukemia (CML), acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL). However, disease relapse is a major cause of treatment failure, and salvage treatment options for these patients are limited. Patients can either be treated with an additional course of conventional chemotherapy or a second round of HDC and repeat allogeneic transplantation. Conventional chemotherapy is unlikely to result in a complete durable remission, and the morbidity and mortality of a second allogeneic transplant is unacceptably high. Furthermore, patients with CML have been treated with interferon. While this treatment can be associated with normalization of peripheral blood counts, interferon fails to eradicate the malignant clone of cells.
Donor lymphocyte infusion (DLI), also known as donor leukocyte or buffy coat infusion, has been used in an attempt to stimulate a donor-versus-leukemia (GVL) reaction and thus eradicate the malignant clone of cells. Donor lymphocyte infusion entails the collection (from the original donor) of peripheral lymphocytes during an apheresis procedure; donors generally undergo 2 to 8 procedures. The lymphocytes are then simply infused into the patient either immediately or after frozen storage. Donor lymphocyte infusion differs from allogeneic bone marrow transplantation in that it is not preceded by chemotherapy and T cells are not depleted. Lymphocyte infusion with a defined T-cell dose can cause a profound GVL effect and is an effective form of salvage immunotherapy in allogeneic marrow transplanted recipients. The advantage in using DLI versus second allogeneic transplantation is the lower treatment-related morbidity and mortality.
The GVL effect is a well-described phenomenon, which is associated with the presence of graft-versus-host disease (GVHD). For example, the likelihood of relapse post-allogeneic transplantation is lower in those patients who experience either acute or chronic GVHD. In addition, there is a higher rate of relapse in patients receiving a syngeneic (identical twin) transplant compared to allogeneic transplant. However, the presence of GVL is not dependent on the presence of GVHD. For example, the rate of leukemic relapse is higher in patients receiving T- cell depleted allogeneic marrow, even after controlling for the degree of GVHD. This observation suggests that there may be a distinct subset of T cells responsible for GVL. Donor lymphocyte infusion attempts to harness the anti-leukemic properties of donor T cells.
In a recent review on adoptive allogeneic cellular therapy, Peggs and Mackinnon (2001) stated that DLI is effective in generating anti-tumor responses, especially for relapsed chronic-phase CML. Response rates and durability appear lower with myeloma, AML and myelodysplasia syndrome, and minimal with ALL. There is relatively little data on indolent lymphoid malignancies. This is in agreement with the observation of Slavin and associates (2001) who reported that pre-clinical and clinical studies have indicated that much more effective eradication of the host immunohematopoietic system cells can be attained by adoptive allogeneic cellular therapy with DLI following bone marrow transplantation. Thus, eradication of blood cancer cells, particularly in patients with CML and, less frequently, in patients with other hematological malignancies, can frequently be achieved despite the complete resistance of such tumor cells to maximally tolerated doses of chemo- and radio-therapy.
In a review on DLI for the treatment of hematologic malignancies in relapse following allogeneic blood or marrow transplantation, Luznik and Fuchs (2002) reported that DLI induces complete remissions in the majority of patients with CML in early-stage relapse and in less than 30 % of patients with relapsed acute leukemia, myelodysplasia, and multiple myeloma. Remissions of chronic-phase CML induced by DLI are durable, but as many as half of patients with other diseases ultimately relapse.
Pre-planned DLI has also been used as part of transplant protocols in persons with hematologic malignant diseases who have not relapsed. Donor lymphocyte infusion is intended to facilitate establishment of full donor chimerism (complete donor stem cell grafting in the recipient's bone marrow) and potentiation of anti-tumor effect (graft-versus-tumor reaction) (Cheong et al, 2002).
There is also ongoing research on the genetic modification of donor lymphocytes. Transplantation of suicide gene modified allogeneic T lymphocytes is an approach to prevent T-cell mediated GVHD while preserving the GVL effect of an allograft. However, existing techniques allow insufficient transduction of T lymphocytes. Further investigation is needed to develop more efficient gene transfer protocols and is possible value in the treatment of hematological malignancies.
Beitinjaneh et al (2012) stated that the role of DLI in mediating the graft-versus-myeloma (GVM) effect after allogeneic hematopoietic stem cell transplant (allo-HCT) is not clearly defined. These investigators evaluated the safety and utility of DLI in patients with either persistent or recurrent multiple myeloma (MM) after allo-HCT. A total of 23 patients with MM received DLI after allo-HCT between July 1996 and June 2008 were included in this study. Eight patients received preemptive DLI for residual disease (RD) while 15 patients received DLI for the treatment of recurrent or progressive disease (PD). These researchers evaluated the response to DLI and the factors that may predict a response. Median DLI dose was 3.3 × 10(7) CD3 + cells (range of 0.5 to 14.8 × 10(7)). Grade II to IV acute GVHD was seen in 5 patients (22 %). Median follow-up in surviving patients was 24 months. Five of 23 patients (22 %) achieved a complete or a very good partial response (2 CR, 3 VGPR), while 8 patients (34 %) had stable disease (SD) after the DLI. Patients who received DLI for RD had a higher response rate (greater than or equal to VGPR 50 % versus 7 %, p = 0.03), a longer overall survival (28.3 versus 7.6 months, p = 0.03) and a trend toward longer progression-free survival (11.9 versus 5.2 months, p = 0.1). In this largest single institution study, the authors concluded that the use of preemptive, non-manipulated DLI for RD after reduced-intensity conditioning allo-HCT is encouraging, and it was associated with a higher response rate and a longer overall survival when given preemptively. They stated that the role of DLI needs to be further explored in prospective clinical trials.
CPT Codes / HCPCS Codes / ICD-9 Codes
CPT codes covered if selection criteria are met:
38204 - 38205, 38207 - 38230
Other CPT codes related to the CPB:
86812 - 86822
HCPCS codes covered if selection criteria are met:
Bone marrow or blood-derived stem-cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and post-transplant care in the global definition
ICD-9 codes covered if selection criteria are met:
204.00 - 204.01
Acute lymphoid leukemia
205.00 - 205.01
Acute myeloid leukemia
205.10 - 205.11
Chronic myeloid leukemia
V42.81 - V42.82
Bone marrow or peripheral stem cells replaced by transplant status
The above policy is based on the following references:
Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462-2465.
Cullis JO, Jiang YZ, Schwarer AP, et al. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood. 1992;79:1379-1381.
Kolb HK, Mittermuller J, Hertenstein H, et al. High dose therapy and bone marrow transplantation. Adoptive immunotherapy in human and canine chimeras - the role of interferon alfa. Semin Hematol. 1993;30:37-39.
Drobyski WR, Keever CA, Roth MS, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood. 1993;82:2310-2318.
van Rhee R, Cullis JO, Spencer A, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood. 1994;83:3377-3383.
Porter DL, Roth MS, McGarigle C, et al. Induction of graft vs host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994;330:100-106.
Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15(2):433-444.
Slavin S, Nagler A, Aker M, et al. Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders. Rev Clin Exp Hematol. 2001;5(2):135-146.
Luznik L, Fuchs EJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control. 2002;9(2):123-137.
Ishikawa J, Maeda T, Kashiwagi H, et al. Successful second allogeneic peripheral blood stem cell transplantation and donor lymphocyte infusion in patients with relapsed acute leukemia using the same donors as for the initial allogeneic bone marrow transplantation. Bone Marrow Transplant. 2003;31(11):1057-1059.
Raiola AM, Van Lint MT, Valbonesi M, et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: A study on 593 infusions. Bone Marrow Transplant. 2003;31(8):687-693.
Bethge WA, Hegenbart U, Stuart MJ, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood. 2004;103(3):790-795.
Vela-Ojeda J, Garcia-Ruiz Esparza MA, Reyes-Maldonado E, et al. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: Prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes. Ann Hematol. 2004;83(5):295-301.
Ballester OF, Fang T, Raptis A, et al. Adoptive immunotherapy with donor lymphocyte infusions and interleukin-2 after high-dose therapy and autologous stem cell rescue for multiple myeloma. Bone Marrow Transplant. 2004;34(5):419-423.
Cheong SK, Eow GI, Leong CF. Non-myeloablative conditioning for hemopoietic stem cell transplantation—does it work? Malays J Pathol. 2002;24(1):1-8.
Huang XJ, Liu DH, Liu KY, et al. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica. 2007;92(3):414-417.
Porter DL, Antin JH. Donor leukocyte infusions in myeloid malignancies: New strategies. Best Pract Res Clin Haematol. 2006;19(4):737-755.
Levenga H, Woestenenk R, Schattenberg AV, et al. Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion. Bone Marrow Transplant. 2007;40(6):585-592.
Heaney NB, Copland M, Stewart K, et al. Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia. Blood. 2008;111(10):5252-5255.
Tomblyn M, Lazarus HM. Donor lymphocyte infusions: The long and winding road: How should it be traveled? Bone Marrow Transplant. 2008;42(9):569-579.
Dvorak CC, Gilman AL, Horn B, et al. Clinical and immunologic outcomes following haplocompatible donor lymphocyte infusions. Bone Marrow Transplant. 2009;44(12):805-812.
Thomson KJ, Morris EC, Milligan D, et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol. 2010;28(23):3695-3700.
Roddie C, Peggs KS. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther. 2011;11(4):473-487.
Kamimura T, Miyamoto T, Kawano N, et al. Successful treatment by donor lymphocyte infusion of adult T-cell leukemia/lymphoma relapse following allogeneic hematopoietic stem cell transplantation. J Hematol. 2012;95(6):725-730.
Karasu GT, Yesilipek MA, Karauzum SB, et al. The value of donor lymphocyte infusions in thalassemia patients at imminent risk of graft rejection following stem cell transplantation. Pediatr Blood Cancer. 2012;58(3):453-458.
Beitinjaneh AM, Saliba R, Bashir Q, et a. Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. Leuk Lymphoma. 2012 Mar 1. [Epub ahead of print]
Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.